From the press release archive
Medicine 2024-07-08 1 min read

Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity

JAMA Internal Medicine
Published 2024-07-08 · Original archive entry · Explore research explainers
About The Study: In this population of adults with overweight or obesity, use of tirzepatide was associated with significantly greater weight loss than semaglutide. Future study is needed to understand differences in other important outcomes. 

Corresponding Author: To contact the corresponding author, Nicholas L. Stucky, M.D., email nicholass@truveta.com.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamainternmed.2024.2525)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.2525?guestAccessKey=1d98a3bc-0a11-444c-a21a-2b875588f3f0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=070824

END
From the original Press-News collection. Issuers of news releases are responsible for the accuracy of their content.